Altria
MO
$70.61
+2.36%
Altria Group, Inc. is a US-focused consumer defensive tobacco company whose subsidiaries — Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Horizon Innovations — manufacture and sell cigarettes, smokeless tobacco, machine-made cigars, heated tobacco, and nicotine pouches, with Marlboro commanding roughly 40% US cigarette share. It is the dominant incumbent in a structurally declining domestic tobacco market, distinguished by pricing power, an exceptional dividend record, and a portfolio of non-core equity stakes including 8% of Anheuser-Busch InBev and 41% of Cronos. The current investor narrative centers on whether relentless price/mix increases can outrun accelerating cigarette volume declines, with the July 2026 Q2 earnings miss and lowered volume trajectory reigniting that debate. Simultaneously, the company's 57-year dividend growth streak, a freshly raised quarterly payout, and a roughly 7% yield keep income investors engaged, while the slow-scaling smoke-free portfolio (Njoy vaping, On! pouches, and the Japan Tobacco heated-tobacco JV) remains the key swing factor for the long-term thesis.…
MO
Altria
$70.61
Related headlines
Investment Opinion: Should I buy MO Today?
We rate Altria as a Hold, balancing its attractive 7.20% dividend yield and deep valuation discount against structural volume declines and a stretched payout ratio. The analyst consensus is also 'hold' with an average target of $70.00, implying just 1.5% upside from the current $68.98, suggesting the stock is fairly valued at present. The core thesis is that the high dividend and low beta provide defensive income, but capital appreciation is likely limited until smoke-free products meaningfully offset cigarette declines.
The supporting evidence includes a forward PE of 11.76x, which is a 25-35% discount to the staples sector, and a PS ratio of 4.80x near the low end of its historical range. Revenue grew 20.12% year-over-year in Q1 2026, but this was against a weak prior-year quarter; sequentially, revenue has been volatile. Profitability remains elite with a 34.50% net margin and 72.21% gross margin, and free cash flow of $8.62 billion TTM comfortably covers the dividend. However, the payout ratio of 100.19% and coverage ratio of 1.24x are red flags.
The biggest risks that could invalidate the thesis are a dividend cut, accelerated volume declines, and regulatory intervention. The rating would upgrade to Buy if the forward PE compresses below 10x or if smoke-free volumes show sustained double-digit growth, and downgrade to Sell if the payout ratio exceeds 110% or if revenue growth turns negative. Relative to its history and peers, Altria appears undervalued on a PE basis, but the discount is justified by its declining core business; thus, it is fairly valued considering the risks.
Sign up to view all
MO 12-Month Price Forecast
Altria presents a classic income-versus-decline dilemma: the 7.20% dividend yield and low beta appeal to income investors, but the structural decline in cigarette volumes and stretched payout ratio limit upside. The stock is fairly valued at 14x trailing earnings, with a forward PE of 11.76x reflecting skepticism about future growth. Analyst sentiment is neutral, with a consensus hold and a target price just 1.5% above the current price. We would upgrade to bullish if smoke-free volumes show sustained acceleration or if the payout ratio improves below 90%, and downgrade to bearish if volume declines accelerate or the dividend is cut. Given the balanced risk/reward, a neutral stance is appropriate for the next 12 months.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $70.00 and implied upside of -0.9% versus the current price.
Average Target
$70.00
0 analysts
Implied Upside
-0.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$58 - $82
Analyst target range
Coverage is moderate with 11 analysts, and sentiment is decidedly neutral: the consensus recommendation is "hold" with a recommendation mean of 2.64 (where 1 is strong buy and 5 is strong sell), and the average target price of $70.00 implies just +1.5% upside from the current $68.98. The distribution skews cautious, with recent actions showing UBS reiterating Buy (July 2026), B of A Securities reiterating Buy (April 2026), but Barclays maintaining Underweight (May 2026) and Citigroup staying Neutral (May 2026) — a split that mirrors the income-versus-decline debate. Given the stock trades within a hair of consensus fair value, the market is effectively saying Altria is fully priced at current fundamentals, and the 7.20% dividend yield, not capital appreciation, is the primary return driver. The target range is wide at $58.00 to $82.00, a $24 spread that equals roughly 35% of the current price and signals genuine disagreement about the trajectory of cigarette volumes and smoke-free adoption. The high target of $82.00 (about +19% upside) likely assumes successful smoke-free scaling, stable pricing power, and multiple expansion toward the low-to-mid teens on forward earnings, while the low target of $58.00 (about -16% downside) prices in accelerating volume declines, margin compression, and pressure on the dividend. The tight clustering of EPS estimates ($6.59 to $6.80, a range of just 3%) contrasts sharply with the wide price-target spread, indicating that analysts broadly agree on near-term earnings but disagree violently on the multiple the market should assign them. With no recent upgrades and a persistent Underweight from Barclays, the burden of proof remains on management to demonstrate that smoke-free products can offset the secular decline in combustibles.
Drowning in data?
Find the real signal!
Bulls vs Bears: MO Investment Factors
The bear case currently has stronger evidence, primarily due to the accelerating decline in cigarette volumes and the stretched dividend payout ratio, which together threaten the core investment thesis. The bull case rests on the stock's deep valuation discount, high dividend yield, and the optionality of smoke-free products, but these are not yet sufficient to offset the structural challenges. The most important tension is whether Altria's pricing power can continue to outpace volume declines; if it cannot, the dividend may be at risk, and the stock could de-rate further. Conversely, if smoke-free products begin to scale and offset combustibles, the multiple could expand toward sector averages. Given the recent earnings miss and cautious analyst sentiment, the risk/reward appears balanced but skewed to the downside until there is clearer evidence of volume stabilization or smoke-free success.
Bullish
- Exceptional dividend yield and growth streak: Altria offers a 7.20% dividend yield, more than triple the Consumer Defensive sector average, backed by a 57-year streak of annual dividend increases. The company recently raised its quarterly payout by nearly 5%, demonstrating continued commitment to shareholder returns despite volume headwinds.
- Deeply discounted valuation versus peers and history: The stock trades at a trailing PE of 14.03x and forward PE of 11.76x, a 25-35% discount to the broader staples sector which typically trades in the high-teens to low-20s multiple range. The PS ratio of 4.80x sits near the low end of its historical range, suggesting the market is overly punitive.
- Elite profitability and strong free cash flow: Altria generates a 34.50% net margin and 72.21% gross margin, with $8.62 billion in trailing free cash flow. Q1 2026 operating cash flow of $2.32 billion comfortably covered $1.78 billion in dividends and $93 million in capex, highlighting the cash-generative nature of the business.
- Low beta defensive profile with income appeal: With a beta of 0.494, Altria moves at roughly half the market's volatility, making it an attractive defensive holding for income-focused portfolios. The 7.20% yield provides a substantial cushion against price fluctuations, and the stock has gained 20.36% year-to-date, outperforming the S&P 500's 12.08% YTD gain.
Bearish
- Accelerating cigarette volume declines: The July 2026 Q2 earnings miss and lowered volume trajectory underscore the structural decline in combustible tobacco. Smokeable Products still account for roughly 88% of revenue ($4.76 billion of $5.43 billion in Q1 2026), so any acceleration in volume declines directly threatens the top line and the sustainability of price increases.
- Dividend payout ratio near 100%: The payout ratio of 100.19% means the dividend currently consumes essentially all reported net income, leaving little margin for error. With a dividend-paid-and-capex coverage ratio of just 1.24x, any cash flow deterioration could jeopardize the dividend, which is the primary reason many investors hold the stock.
- Weak balance sheet and negative equity: Debt-to-equity is deeply negative at -7.34, reflecting negative shareholders' equity from decades of buybacks, and the current ratio is a thin 0.61. While free cash flow remains strong, the balance sheet offers limited flexibility, and the company is simultaneously servicing debt, funding buybacks, and paying a premium dividend.
- Analyst consensus implies limited upside: The average analyst target price of $70.00 implies just 1.5% upside from the current $68.98, with a consensus recommendation of 'hold' (mean 2.64). The wide target range of $58 to $82 signals deep disagreement, and the stock trades near consensus fair value, suggesting the market sees it as fully priced.
MO Technical Analysis
Altria is in a choppy, range-bound recovery rather than a clean trend: the stock is up 3.95% over the past year and 20.36% year-to-date, but sits at $68.98, only about 59% of the way up its 52-week range of $54.70 to $77.06. That mid-range positioning signals neither momentum-driven overextension nor a distressed falling knife, but rather a market that has repriced the shares higher off the lows while capping upside near the mid-$70s. The 19.15% maximum drawdown over the past year confirms that this is a stock prone to sharp sentiment-driven air pockets despite its low-beta defensive profile. Recent momentum is bifurcated: the 1-month change of +7.15% is strongly positive and has produced a relative strength versus SPY of +8.21 percentage points, yet the 3-month change of -4.11% is negative and trails SPY by 7.15 points. This divergence — a strong rebound month inside a weak quarter — points to a mean-reversion bounce off the August lows near $63.96 rather than a durable new uptrend, and the 6-month gain of just 1.61% (versus SPY +15.40%) reinforces that the stock has been a relative laggard over the intermediate term. Key levels are well defined: support sits at the 52-week low of $54.70, with a nearer tactical floor around the August swing low of $63.96, while resistance is the 52-week high of $77.06, which also coincides with the late-July rejection zone near $74.92. A decisive breakout above $77 would likely require evidence that smoke-free volumes are inflecting, whereas a breakdown below $63.96 would expose the $54.70 low and validate the volume-decline bears. With a beta of just 0.494, Altria moves at roughly half the market's volatility, which supports larger position sizing for income mandates but also means the stock will not deliver sharp upside torque without a fundamental catalyst.
Beta
0.49
0.49x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$77
Price range past year
Annual Return
+5.9%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +7.5% | -2.0% |
| 3m | +0.6% | +1.4% |
| 6m | +8.4% | +15.0% |
| 1y | +5.9% | +15.7% |
| ytd | +23.2% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Revenue is growing but lumpy: Q1 2026 revenue of $5.428 billion rose 20.12% year-over-year against Q1 2025's $4.519 billion, yet that comparison flatters the trend because the prior-year quarter was unusually weak (net income of just $1.077 billion). Sequentially, revenue has oscillated between $5.251 billion (Q3 2025), $5.846 billion (Q4 2025), and $5.428 billion (Q1 2026), a pattern consistent with pricing gains offsetting volume erosion rather than genuine unit growth. Segment data confirms the concentration risk: Smokeable Products generated $4.758 billion of revenue versus just $669 million from Smokeless Products and $1 million from Other, meaning the declining cigarette franchise still supplies roughly 88% of the top line. The investment case therefore hinges on whether price/mix can keep compounding faster than the volume base shrinks, and the July 2026 earnings miss suggests that math is getting harder. Profitability remains elite by any sector standard: Q1 2026 net income was $2.183 billion on a 40.22% net margin, with gross margin of 64.59% and an operating margin of 54.46%, while the trailing valuation data show a 72.21% gross margin and 34.50% net margin. Margins are nonetheless volatile quarter to quarter — gross margin ranged from 62.11% in Q4 2025 to 72.60% in Q3 2025 — reflecting one-time charges and mix shifts, and the Q4 2025 operating margin of 28.24% was less than half the Q1 2026 level. The company is highly profitable and cash-generative, but the earnings quality is noisy, and the payout ratio of 100.19% signals that the dividend currently consumes essentially all reported net income. The balance sheet is the real constraint: debt-to-equity is deeply negative at -7.34 (reflecting negative shareholders' equity from decades of buybacks), the current ratio is a thin 0.61, and ROE of -198.37% is an artifact of that negative equity base rather than a cash-flow problem. Free cash flow remains substantial at $8.623 billion TTM, and Q1 2026 operating cash flow of $2.324 billion comfortably covered $1.78 billion of dividends plus $93 million of capex, but the dividend payout ratio near 100% and a dividend-paid-and-capex coverage ratio of just 1.24x leave little margin for error. With $1.069 billion of debt repaid in Q1 2026 and cash falling from $4.492 billion to $3.550 billion, Altria is simultaneously servicing debt, funding buybacks ($280 million), and paying a premium dividend — a capital allocation posture that works only as long as cash flow holds.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+20.1%
YoY Comparison
Gross Margin
64.6%
Latest Quarter
Free Cash Flow
$8.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Because Altria is solidly profitable — Q1 2026 net income of $2.183 billion and trailing EPS of $0.0718 on a reported basis with normalized EPS around $1.30 quarterly — the PE ratio is the appropriate primary metric, and the trailing PE of 14.03x against a forward PE of 11.76x implies the market expects meaningful earnings growth ahead. That 16% compression from trailing to forward multiple is consistent with analyst EPS estimates of $6.67 for the coming year, and it frames Altria as a low-multiple, high-yield value stock rather than a growth compounder. The gap also reflects skepticism: investors are willing to pay less than 12x forward earnings for a business with declining unit volumes, which is a classic value-trap discount. On peer comparison, Altria's 14.03x trailing PE and 4.80x PS sit against a Consumer Defensive sector where staples typically trade in the high-teens to low-20s multiple range, implying a discount of roughly 25-35% to the broader group; its EV/EBITDA of 10.89x and EV/Sales of 6.71x similarly screen cheap versus quality staples peers. That discount is partly justified by structural volume decline and regulatory overhang, but the 7.20% dividend yield — more than triple the sector average — and 34.50% net margin argue that the market is over-penalizing a business that still converts a huge share of revenue into cash. Historically, Altria's PE has ranged from roughly 5.2x (Q2 2024) to 23.8x (Q1 2025) on a quarterly basis, with the current 14.03x sitting near the middle of that band and well below the 21.8x recorded in Q4 2025. The PS ratio of 4.80x is near the low end of its own historical range (which has run from roughly 14x to 22x on the quarterly series), suggesting the stock is not expensive relative to its own history. The combination of a mid-band PE and a low-end PS implies the market is pricing modest growth and stable margins — leaving room for multiple expansion if smoke-free volumes stabilize, but also downside if the dividend coverage deteriorates further.
PE
14.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Altria's financial and operational risks are significant, primarily stemming from its reliance on a declining cigarette franchise that generates roughly 88% of revenue. The payout ratio of 100.19% and a dividend coverage ratio of just 1.24x leave little room for error; any cash flow shortfall could force a dividend cut, which would likely trigger a sharp sell-off given the stock's income appeal. Additionally, the balance sheet is constrained by negative equity (debt-to-equity of -7.34) and a thin current ratio of 0.61, limiting financial flexibility. While free cash flow of $8.62 billion TTM is substantial, the company is simultaneously servicing debt, funding buybacks, and paying dividends, a capital allocation posture that works only as long as cash flow holds.
Market and competitive risks include valuation compression if the stock's discount to peers narrows further due to persistent volume declines. Altria trades at a forward PE of 11.76x, well below the staples sector average, but this discount could widen if smoke-free products fail to gain traction. The low beta of 0.494 means the stock is less sensitive to market swings, but it also lacks upside torque without a fundamental catalyst. Regulatory headwinds, such as potential menthol bans or nicotine caps, pose a constant threat, and competition from illicit vapes could undermine the smoke-free portfolio. Recent news highlights the Q2 earnings miss and declining volumes, which have already pressured the stock.
The worst-case scenario involves a perfect storm of accelerating volume declines, margin compression, and a dividend cut. If cigarette volumes decline faster than pricing can offset, revenue and cash flow would shrink, forcing management to cut the dividend to preserve cash. This could drive the stock toward its 52-week low of $54.70, representing a 20.7% decline from the current price of $68.98. The analyst low target of $58.00 implies a 15.9% downside, but a dividend cut could push the stock below that level, especially given the negative equity and limited balance sheet flexibility. In this adverse scenario, investors could lose 20-30% from current levels, not including the loss of dividend income.
FAQ
The key risks include: 1) Dividend sustainability risk, as the payout ratio of 100.19% and coverage ratio of 1.24x leave little margin; a cut would likely cause a sharp price decline. 2) Volume decline risk, with cigarette volumes falling and smokeable products accounting for 88% of revenue; acceleration could pressure cash flows. 3) Regulatory risk, such as potential menthol bans or nicotine caps, which could further reduce volumes. 4) Balance sheet risk, with negative equity and a current ratio of 0.61, limiting financial flexibility. These risks are ranked from most to least severe, with dividend sustainability being the most immediate concern.
Our 12-month forecast for MO includes three scenarios: bull case (25% probability) targeting $77-$82, base case (55% probability) targeting $68-$72, and bear case (20% probability) targeting $55-$58. The base case assumes cigarette volume declines remain in the 4-6% range, offset by price increases, and the dividend is maintained. The most likely scenario is the base case, with the stock trading around the analyst average target of $70.00. Key assumptions include stable regulatory environment and no major acceleration in volume declines. However, if volume declines accelerate or the dividend is cut, the bear case could materialize.
MO appears undervalued on a relative basis, trading at a trailing PE of 14.03x and forward PE of 11.76x, compared to the Consumer Defensive sector's typical high-teens to low-20s multiple. The PS ratio of 4.80x is near the low end of its historical range. However, this discount reflects the market's concern over structural volume declines and regulatory risks. The dividend yield of 7.20% is a key attraction, but the payout ratio near 100% suggests limited room for error. Overall, the stock is fairly valued considering its risk profile, with limited upside unless smoke-free products gain traction.
MO may be a good buy for income-focused investors seeking a high dividend yield, but it carries significant risks. The stock offers a 7.20% dividend yield, more than triple the sector average, and trades at a forward PE of 11.76x, a discount to peers. However, the payout ratio of 100.19% and declining cigarette volumes threaten the dividend's sustainability. Analyst consensus is 'hold' with a target of $70.00, implying just 1.5% upside. Therefore, it is suitable for patient investors who can tolerate the risk of a dividend cut in exchange for current income, but not for those seeking growth.
MO is more suitable for long-term investment, particularly for income-focused investors who can hold through volatility. The stock has a low beta of 0.494, indicating lower volatility than the market, and a 57-year dividend growth streak, making it a classic income holding. However, the structural decline in cigarette volumes means capital appreciation is likely limited, and the dividend may be at risk in the long term. Short-term trading is less attractive due to the lack of clear catalysts and the stock's range-bound behavior. A minimum holding period of 3-5 years is suggested to ride out potential dividend adjustments and benefit from the high yield.
